Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
weight loss
Biotech
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
The combo's weight loss of 14.2% beat semaglutide's 10.2%. Novo is awaiting results from two other trials before readying its diabetes submission.
Darren Incorvaia
Feb 2, 2026 3:01pm
Skye links CB1-Wegovy combo to 22.3% weight loss after a year
Feb 2, 2026 8:08am
Lilly's obesity pill maintains weight lost on injectable GLP-1s
Dec 18, 2025 8:20am
Wave, Structure stocks double on obesity data readouts
Dec 8, 2025 10:50am
Ascletis reports 7.7% weight loss for oral GLP-1 contender
Dec 8, 2025 8:35am
Skye's CB1 blocker fails to reduce weight in obesity study
Oct 6, 2025 7:55am
